Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis
Status:
Completed
Trial end date:
2018-08-06
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the clinical efficacy of UCB7665 as a
chronic-intermittent treatment in subjects with generalized myasthenia gravis (MG) who are
classified as moderate to severe.